HALLE (SAALE), Germany, 12 May 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announces […]
HALLE (SAALE), Germany, 5 May 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its […]
HALLE (SAALE), Germany, 02 May 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), has the honour […]
HALLE (SAALE), Germany, 25 April 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]
The Glutaminyl Cyclase (QC) inhibitor PQ912 demonstrates beneficial effects in a preclinical Huntington´s disease model HALLE (SAALE), Germany, 10 April 2017 – Probiodrug AG (Euronext […]
Last Patient Last Visit (LPLV) reached in the SAPHIR Study, a Phase 2 trial with the Glutaminyl Cyclase (QC) inhibitor PQ912 in early Alzheimer’s Disease (AD) […]
HALLE (SAALE), Germany, 03 April 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]
SAPHIR, the Phase 2a study of PQ912 as a novel treatment for Alzheimer’s disease fully enrolled Favourable results of chronic toxicology studies with PQ912 announced Promising […]
New results of a double pronged-approach to target the neurotoxic amyloid beta species pGlu-Abeta, and an evaluation of new biomarkers in cerebrospinal fluid (CSF) from AD […]